The Drugs Controller General of India has approved the manufacture of this Sars-CoV-2 spike protein recombinant nano-particle vaccine for ‘examination, test, and analysis’,......
The Covid-19 vaccine demonstrated an overall 90.4 per cent efficacy in phase 3 clinical trials, reports Sohini Das IMAGE: The vaccine candidate NVX-CoV2373 has shown 100 per cent protection......
India currently does not have any XBB 1.5 variant-based vaccines available. IMAGE: A healthcare worker prepares a dose of a COVID-19 vaccine. Photograph: ANI Photo New-generation Covid......
An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India's COVID vaccine Covovax as a heterologous booster dose for adults who have......
The Drug Controller General of India has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or......
Serum Institute of India plans to make 300 million doses of AZD1222 by December, and will begin phase-2 trials soon. It has also tied up with Novavax for development and commercialisation of its......
Close on the heels of Hetero Drugs launching Oseltamivir, an anti-bird flu drug, Nasdaq-listed Novavax Inc and Hyderabad-based Bharat Biotech International on Monday announced a strategic......
India's willingness to play a big role in the manufacturing and to allow some of those vaccines to go to other developing countries will be an absolutely critical part of containing the pandemic,......
'Once the trials are successful in India and the UK, we are certain that COVISHIELD will be one of the first vaccines to be introduced.' IMAGE: The Reference Center for Special Immunobiologicals......